# Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451

Study · id `cardio:ct-nct04161001` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04161001](<https://clinicaltrials.gov/study/NCT04161001>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04161001

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 237 participants.

## Technical summary

Registry record NCT04161001. Randomized; double masking; primary purpose treatment. Start 2019-11-20 (anticipated); primary completion 2021-11-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 237 participants (planned count; ClinicalTrials.gov record NCT04161001, source copy `cardio:ctgov-nct04161001-2019-11-13`, retrieved 2026-10-26)
- Planned start: 2019-11-20 (anticipated) (ClinicalTrials.gov record NCT04161001, source copy `cardio:ctgov-nct04161001-2019-11-13`, retrieved 2026-10-26)
- Primary completion: 2021-11-20 (anticipated) (ClinicalTrials.gov record NCT04161001, source copy `cardio:ctgov-nct04161001-2019-11-13`, retrieved 2026-10-26)
- Completion: 2022-02-02 (anticipated) (ClinicalTrials.gov record NCT04161001, source copy `cardio:ctgov-nct04161001-2019-11-13`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04161001, source copy `cardio:ctgov-nct04161001-2019-11-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04161001-2019-11-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451
- Condition: Hypertension, Dyslipidemia
- Intervention (Drug): Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
- Intervention (Drug): Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
- Intervention (Drug): Amlodipine/Olmesartan 10/40mg (Combination drug)
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 7c18904114c66065f84902b400780c4bcbf705ffabed9419cd8c53997c5680a7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
